High Cost Drugs – Jersey
CHANNEL ISLANDS OPPORTUNITY — Jersey Health and Community Services
Governance that prevents recurrence: every high-cost prescription requires documented eligibility confirmation before treatment.
- Collect eligibility criteria evidence from Clinicians — gate-keeping every high-cost prescription
- Using Auto-Approval, ensure Clinicians receive approval to treat eligible patients immediately
- Keep a complete, irrefutable audit trail — preventing recurrence of the rheumatology crisis
- Built-in treatment review triggers — no patient continues on high-cost treatment unnecessarily
Introduction
Paperless Solution — Governance That Prevents Recurrence
A clinician cannot initiate a high-cost treatment without confirming on record that the patient meets the eligibility criteria. Every decision is documented, time-stamped, and retrievable. The audit trail is built at the point of prescribing — not reconstructed afterwards. Jersey's Health and Community Services operates under NICE guidance and the same governance principles as NHS England, making Blueteq immediately applicable without system redesign.
Request History & Document Storage
Every request, approval, and continuation decision is permanently stored and retrievable. If a prescription is challenged — by auditors, by the Government of Jersey, or in future proceedings — the evidence exists and is complete. Blueteq's document storage means no filing is required and all vital data is immediately to hand.
Customised Reporting for Jersey HCS
A full range of reports are available on demand. Jersey HCS management can see at a glance which high-cost medicines are in use, for which patients, against which criteria, and at what cost — information that should have been available and was not.
Without Blueteq
High-cost treatment initiated without evidence of eligibility — the conditions under which treatment is authorised are not recorded at the point of prescribing.
No audit trail for continuation decisions — patients continue on expensive treatments with no systematic review of whether they remain eligible.
No invoice matching — high-cost drug invoices are paid without cross-referencing to approved treatment requests.
Governance failure discovered retrospectively — the problem is identified only when financial or clinical harm has already occurred.
For Commissioners / Stakeholders
- Save on invoice values through discrepancy detection
- Reduce unnecessary spending via eligibility gate-keeping
- Maximise budget impact on patient care
- Match invoices to requests in minutes
- Combined clinical + financial data in one secure system
- Advanced reporting drives quality improvements
For Hospitals / Providers
- Clinicians guided through eligibility criteria at prescribing
- Auto-approval for eligible patients — average 5–10 minutes
- Clear evidence base for every treatment decision
- Simplified submissions through one unified platform
- Full visibility of request status and historical data
- Track and improve patient outcomes with built-in reporting
"The Blueteq HCD system plays an essential role in ensuring patients receive appropriate, evidence-based treatments while keeping costs in check."
100%
Prescriptions gate-kept
Direct
Invoice savings recovered
24/7
Audit trail accessible
5 min
Average approval time
WHY CHOOSE US
Unique Benefits Summary: High Cost Drugs - Jersey
- Prevents recurrence — every high-cost prescription requires documented eligibility confirmation before treatment
- Irrefutable audit trail — built at the point of prescribing, not reconstructed afterwards
- Invoice matching recovers value through discrepancy identification
- Built-in treatment review triggers — no patient continues unnecessarily
- Follows NICE guidance — immediately applicable to Jersey HCS without redesign
- IFR module available — governance for individual funding requests
- No software to install and maintain locally — web-based, simple subscription
- UK-Based. Employee-Owned. Independently Governed.
UK-Based. Employee-Owned. Independently Governed.
Blueteq is an employee-owned company headquartered in Havant, Hampshire. All data is held on Blueteq’s own UK infrastructure, subject to UK law and governance. There are no external shareholders, no overseas parent company, and no venture capital or private equity interests.
